The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
M. Simonelli
No relevant relationships to disclose
P. A. Zucali
No relevant relationships to disclose
R. De Sanctis
No relevant relationships to disclose
E. Lorenzi
No relevant relationships to disclose
F. De Vincenzo
No relevant relationships to disclose
L. Rimassa
No relevant relationships to disclose
M. C. Tronconi
No relevant relationships to disclose
N. Personeni
No relevant relationships to disclose
G. Masci
No relevant relationships to disclose
M. Zuradelli
No relevant relationships to disclose
M. Perrino
No relevant relationships to disclose
M. Bertossi
No relevant relationships to disclose
L. Giordano
No relevant relationships to disclose
A. Santoro
No relevant relationships to disclose